1. Introduction {#s1}
===============

It has been firmly shown that cardiac resynchronization therapy (CRT) is an established treatment option for a subgroup of appropriately selected patients with diverse heart failure (HF) severity to improve left ventricular (LV) reverse remodeling, reduce clinical symptoms and decrease cardiovascular mortality and morbidity.[@b1] Despite the indubitable advantages of CRT, the response to CRT appears to vary substantially and up to approximately 30% patients fail to benefit from CRT, leading to a desire to identify of so-called non-responders prior to CRT implantation.[@b2] High sensitivity C-reactive protein (hsCRP) is synthesized and secreted by hepatocytes in response to proinflammatory cytokines, namely IL-6, and it seems to be the most reliable biomarkers to assess inflammatory processes in clinical practice.[@b3] Plasma hsCRP levels are commonly elevated in patients with depressed LV function and have been regarded as an independent and powerful predictor of adverse cardiac events in advanced HF patients.[@b4]--[@b6] However, data regarding the association of hsCRP levels with LV reverse remodeling as well as long-term outcome in the subset of patients with HF receiving CRT are limited, and the value of hsCRP levels in predicting mortality or morbidity in CRT recipients currently remains unclear.

Therefore, aims of the present study were to: (1) investigate the relation between baseline hsCRP levels and long-term outcome after CRT; (2) evaluate the impact of CRT on the concentrations of hsCRP during 6-month follow-up; and (3) explore the prognostic value of follow-up hsCRP assessment following CRT.

2. Methods {#s2}
==========

2.1. Study population {#s2a}
---------------------

A total of 232 consecutive chronic HF patients who underwent successful implantation of a CRT system between January 1999 and December 2013 at Fuwai hospital were included. All subjects received CRT therapy according to the accepted criteria of New York Heart Association (NYHA) class III or IV despite optimal medical therapy, LV ejection fraction (LVEF) ≤ 35%, QRS width ≥ 120 ms and left ventricular end-diastolic diameter (LVEDD) ≥ 55 mm.[@b1],[@b7] Data including demographics, echocardiographic parameters, laboratory values, and medications at the initial evaluation were retrospectively obtained from the electronic medical record. Long-term follow-up evaluations after device implantation were performed through the chart review, device interrogation or a telephone interview. All of the patients signed informed consent forms, and the study complied with the Declaration of Helsinki and was approved by the Research Ethics Board of Fuwai Hospital.

2.2. Definitions {#s2b}
----------------

Venous blood samples were obtained from the entire patient cohort before CRT implantation for measurement of hsCRP. We used the recommended conventional cut-off value for hsCRP of 3.0 mg/L provided by consensus conference of the Centers of Disease Control (CDC) and the American Heart Association (AHA) on the use of hsCRP in clinical practice,[@b8] and patients at baseline were dichotomized into high (\> 3.0 mg/L) and low hsCRP groups (≤ 3.0 mg/L) according to enrollment hsCRP levels. During 6-month follow-up, there was a subset of 198 (85.3%) patients with routinely acquired blood samples for hsCRP assessment. Follow-up changes in hsCRP levels from baseline to 6-month were categorized as high/high (baseline/6-month), high/low, low/high, and low/low. Patients were classified as responders to CRT in terms of improvement in NYHA class by ≥ 1 combined with an absolute increase ≥ 5% in LVEF during 6-month follow-up.[@b9] Patients who died, underwent heart transplantation or hospitalized for HF within 6-month were regarded as non-responders. Primary endpoint events were defined as all-cause mortality (due to HF, sudden cardiac death, or non-cardiac cause), cardiac transplantation and hospitalizations for decompensated HF.

2.3. Echocardiographic evaluation {#s2c}
---------------------------------

Echocardiograms were obtained at baseline for all patients and at 6-month were available for 215 (92.7%) patients, respectively. Echocardiographic parameters including the left atrium diameters (LAD) and LVEDD were measured using a commercially available system (iE33; Philips Medical Systems) equipped with a 3.5-MHz transducer according with the recommendations of the American Society of Echocardiography protocols.[@b10] LVEFs were calculated using the modified biplane Simpson\'s rule from apical imaging planes.[@b11] The severity of mitral regurgitation (MR) was assessed as the average area of the regurgitant jet area to left atrium using the color-flow Doppler images at the parasternal long-axis.[@b12]

2.4. CRT implantation procedure {#s2d}
-------------------------------

The LV lead was inserted transvenously via the subclavian route. A coronary sinus venogram was obtained using a balloon catheter, and the LV pacing lead was inserted through the coronary sinus with the help of an 8-F or 9-F guiding catheter and positioned as far as possible in the venous system, preferably in the lateral or posterolateral vein. The atrial and right ventricular leads were placed routinely in the right atrial appendage and the right ventricular apex. All leads were connected to a dual-chamber biventricular implantable cardiac device. The decision to use a CRT device with defibrillator function (CRT-D) was based on primary or secondary prevention for episodes of sustained ventricular tachycardia or inducible ventricular arrhythmia. The atrioventricular interval was optimized by Ritter\'s method with transthoracic echocardiography.

2.5. Statistics {#s2e}
---------------

Continuous data are presented as mean ± SD, and dichotomous data are expressed as numbers and percentages. Comparison of data between patient groups was performed using the independent-samples *t* test for continuous data. The Fisher\'s exact tests or *χ*^2^ tests were used to compare dichotomous data. Survival of patients was evaluated with the Kaplan-Meier method and log rank test was utilized to compare the survival curves. Variables significant in univariate analysis were entered in a multivariate Cox proportional hazards model to determine the independent predictors of event-free survival using a backward stepwise selection. At each step, the least significant variable was discarded from the model until all variables in the model reached a *P* value below 0.25. The analyses were conducted using the SPSS 16.0 software (SPSS, Chicago, IL, USA). *P* \< 0.05 was considered statistically significant.

3. Results {#s3}
==========

3.1. Baseline characteristics {#s3a}
-----------------------------

[Table 1](#jgc-11-04-296-t01){ref-type="table"} shows the baseline demographics and clinical characteristics of 232 patients according to the initial hsCRP levels. Patients were subdivided into high (\> 3 mg/L) and low (≤ 3 mg/L) hsCRP groups, with 105 patients in the high hsCRP group (7.8 ± 4.3 mg/L) and 127 subjects in the low hsCRP group (1.3 ± 1.6 mg/L). The mean age of study population was 59.7 ± 10.4 years, and 154 (66.4%) patients were male. CRT recipients showed depressed LV systolic function (mean LVEF, 27.7% ± 6.7%) with QRS prolongation (158.1 ± 20.0 ms). Compared to those with low hsCRP, patients with high hsCRP tended to be much older and more symptomatic, and presented less left bundle branch block (LBBB) and larger LAD during their initial evaluation. In addition, the concentrations of biochemical markers including serum creatinine, blood urea nitrogen (BUN) and N-terminal pro-brain natriuretic peptide (NT-proBNP) were significantly higher in patients with elevated hsCRP than in those with low hsCRP. No differences regarding the comorbidities and treatment strategies between elevated hsCRP group and low hsCRP group existed at baseline.

###### Clinical baseline characteristics of the study population according to the enrolled hsCRP levels.

                                hsCRP ≤ 3 mg/L (*n* = 127)   hsCRP \> 3 mg/L (*n* = 105)   *P*-value
  ---------------------------- ---------------------------- ----------------------------- -----------
  Age, yrs                             57.6 ± 10.2                   62.2 ± 10.0             0.001
  Male                                  83 (65.4%)                   71 (67.6%)              0.781
  LBBB                                 108 (85.0%)                   78 (74.3%)              0.041
  NYHA class                            3.1 ± 0.3                     3.3 ± 0.4              0.013
  Intrinsic QRS duration, ms           157.5 ± 18.4                 158.9 ± 21.8             0.594
  Serum creatinine, mg/dL               1.1 ± 0.4                     1.3 ± 0.5              0.001
  BUN, mmol/L                           8.1 ± 2.8                     9.5 ± 4.7              0.014
  hsCRP, mg/L                           1.3 ± 1.6                     7.8 ± 4.3            \< 0.001
  NT-proBNP, pmol/L                  1879.3 ± 1286.7               2487.9 ± 2040.3           0.011
  Comorbidities                                                                           
   Ischaemic cardiomyopathy             25 (19.7%)                   29 (27.6%)              0.155
   Hypertension                         43 (33.9%)                   39 (37.1%)              0.602
   Hypercholesterolemia                 45 (35.4%)                   29 (27.6%)              0.204
   Diabetes mellitus                    27 (25.7%)                   26 (20.5%)              0.344
   Atrial fibrillation                   7 (5.5%)                    11 (10.5%)              0.159
   PAH                                  25 (19.7%)                   32 (30.5%)              0.057
  Echocardiography                                                                        
   LVEF, %                              27.6 ± 6.8                   27.8 ± 6.4              0.785
   LAD, mm                              43.4 ± 7.1                   45.5 ± 7.7              0.033
   LVEDD, mm                            71.2 ± 9.0                   71.0 ± 10.2             0.866
   RVEDD, mm                            21.7 ± 4.9                   22.7 ± 5.5              0.130
   MR grade                             2.5 ± 0.9                     2.5 ± 1.0              0.826
  Treatments                                                                              
   ACEI or ARB                         103 (81.1%)                   83 (79.0%)              0.696
   β-blockers                          118 (92.9%)                   100 (95.2%)             0.459
   Digoxin                              93 (73.2%)                   76 (72.4%)              0.855
   Amiodarone                           27 (21.3%)                   26 (24.8%)              0.527
   CRT-D                                59 (46.5%)                   62 (59.0%)              0.056

The data are presented as the *n* (%) or the means ± SD. ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; BUN: blood urea nitrogen; CRT-D: cardiac resynchronization therapy-defibrillator; hsCRP: high-sensitivity C-reactive protein; LAD: left atrial diameter; LBBB: left bundle branch block; LVEDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; LVMI: left ventricular mass index; MR: mitral regurgitation; NT-proBNP: N-terminal pro-brain natriuretic peptide; NYHA class: New York Heart Association functional class; PAH: pulmonary arterial hypertension; RVEDD: right ventricular end-diastolic diameter.

3.2. Baseline hsCRP and clinical outcome {#s3b}
----------------------------------------

In our study, the mean follow-up duration was 31.3 ± 31.5 months. Thirty-two patients (13.8%) experienced all-cause mortality including 24 patients with HF-related death, five patients with sudden death and three patients with non-cardiac death. Four patients (1.7%) underwent heart transplantation and 56 patients (24.1%) were hospitalized for worsening HF. A total of 59 patients (25.4%) experienced the combined endpoint of death or HF hospitalizations. Over the long-term follow-up, patients with hsCRP \> 3 mg/L had a significantly lower probability of surviving without suffering the combined endpoint of death or HF hospitalizations as compared to those with hsCRP ≤ 3 mg/L (log-rank *P* \< 0.01, [Figure 1](#jgc-11-04-296-g001){ref-type="fig"}). After controlling for confounding factors, elevated hsCRP levels (\> 3 mg/L) at baseline were shown to independently predict adverse clinical response (HR: 2.39, 95%CI: 1.28--4.47, *P* = 0.006, [Table 2](#jgc-11-04-296-t02){ref-type="table"}). When assessed as a continuous variable, each 1 mg/L increase in hsCRP was associated with a corresponding 8.3% increase (*P* = 0.005) in the risk of the combined endpoint of death or HF hospitalizations.

![Kaplan-Meier estimates of the cumulative probability of the combined endpoint of death or HF hospitalizations in CRT patients with high (\> 3 mg/L) and low (≤ 3 mg/L) baseline hsCRP.\
CRT: cardiac resynchronization therapy; HF: heart failure; hsCRP: high sensitivity C-reactive protein.](jgc-11-04-296-g001){#jgc-11-04-296-g001}

3.3. Effect of CRT on hsCRP levels {#s3c}
----------------------------------

During 6-month follow-up, a total of 170 of 232 (73.3%) patients were classified as responders. Baseline hsCRP values as well as 6-month hsCRP levels were significantly lower in patients who responded to CRT than in those who did not (*P* = 0.001 and *P* \< 0.001, respectively), with a mean 0.5 ± 4.1 mg/L reduction from baseline for patients who were responders and 1.7 ± 6.1 mg/L increase from baseline for those who were non-responders (*P* = 0.018). Both baseline and 6-month hsCRP values for responders and non-responders to CRT are displayed in [Figure 2](#jgc-11-04-296-g002){ref-type="fig"}.

###### Uni- and multivariate Cox proportional hazards models for death or heart failure hospitalizations.

                                               Univariable                     Multivariable                      
  ---------------------------------------- ------------------- -------------- --------------- ------------------- --------------
  Age, yrs                                  1.02 (0.99--1.05)      0.133                                          
  Male                                      1.51 (0.85--2.68)      0.160                                          
  Ischaemic cardiomyopathy                  1.15 (0.62--2.13)      0.666                                          
  QRS duration, ms                          0.99 (0.98--1.01)      0.406                                          
  LBBB                                      0.54 (0.30--0.96)    **0.034**                                        
  NYHA class                                2.59 (1.52--4.41)   **\< 0.001**                                      
  LVEDD, mm                                 1.01 (0.98--1.04)      0.575                                          
  LVEF,%                                    1.01 (0.97--1.05)      0.663                                          
  MR grade                                  1.57 (1.14--2.12)    **0.005**                                        
  Serum creatinine, per 1 mg/dL increase    4.36 (2.66--7.17)   **\< 0.001**                   2.88 (1.71--4.85)   **\< 0.001**
  BUN, per 1 mmol/L increase                1.13 (1.06--1.20)   **\< 0.001**                                      
  HsCRP \> 3mg/L                            3.56 (2.04--6.22)   **\< 0.001**                   2.39 (1.28--4.47)    **0.006**
  NT-proBNP, per 100 pmol/L increase        1.04 (1.02--1.05)   **\< 0.001**                   1.03 (1.01--1.04)    **0.003**
  ACE-I or ARB                              0.78 (0.40--1.50)      0.451                                          
  β-blockers                                0.04 (0.01--2.66)      0.134                                          
  CRT-D                                     0.57 (0.34--0.97)    **0.038**                                        

ARB: angiotensin receptor blocker; BUN: blood urea nitrogen; CRT-D: cardiac resynchronization therapy-defibrillator; hsCRP: high-sensitivity C-reactive protein; LBBB: left bundle branch block; LVEDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; LVMI: left ventricular mass index; MR: mitral regurgitation; NT-proBNP: N-terminal pro-brain natriuretic peptide; NYHA class: New York Heart Association functional class.

![Mean baseline, 6-month, and absolute changes in hsCRP in patients with and without response to CRT at 6-month follow-up.\
Absolute changes in hsCRP were calculated as the difference between 6 month and baseline hsCRP levels, among the 198 patients with available paired baseline and 6-month hsCRP assessment. ^Φ^*P* = 0.001, ^δ^*P* \< 0.001, ^σ^*P* = 0.018. CRT: cardiac resynchronization therapy; hsCRP: high sensitivity C-reactive protein.](jgc-11-04-296-g002){#jgc-11-04-296-g002}

3.4. HsCRP change and subsequent outcome {#s3d}
----------------------------------------

The survival curve for all-cause mortality or HF hospitalizations among patients with for each of the baseline to 6-month hsCRP change group is shown in [Figure 3](#jgc-11-04-296-g003){ref-type="fig"}. During long-term follow-up, compared with those with low/high baseline and low 6-month hsCRP values, patients with low/high baseline and high 6-month hsCRP values displayed higher rate of the combined endpoint of death or HF hospitalizations (log-rank *P* \< 0.01). After multivariate adjustment, compared with those with 6-month hsCRP values which stayed low, patients with 6-month hsCRP levels that remained high experienced the highest rate of death or HF hospitalizations (HR: 7.6, *P* \< 0.001), and patients whose levels increased from low baseline to high 6-month hsCRP values suffered secondary risk (HR: 2.9, *P* = 0.079), and patients whose levels declined from a high baseline to low 6-month hsCRP values underwent similar risk (HR: 1.4, *P* = 0.576, [Table 3](#jgc-11-04-296-t03){ref-type="table"}). When assessed as a continuous variable, each 1 mg/L increase in 6-month hsCRP levels was related to a corresponding 9.6% increase (*P* = 0.001) in the risk of death or HF hospitalizations.

![Kaplan-Meier estimates of the cumulative incidence of the combined endpoint of death or HF hospitalizations according to the pattern of hsCRP change after six months of CRT.\
BL: baseline; 6: 6 months; HF: heart failure; hsCRP: high sensitivity C-reactive protein; (+): high hsCRP group (\> 3 mg/L); (−): low hsCRP group (≤ 3 mg/L).](jgc-11-04-296-g003){#jgc-11-04-296-g003}

3.5. HsCRP change and LV reverse remodeling {#s3e}
-------------------------------------------

The relationship between the pattern of hsCRP change and LV reverse at 6-month among the 198 patients with paired echocardiograms and hsCRP values is shown in [Figure 4](#jgc-11-04-296-g004){ref-type="fig"}. There were no significant differences in baseline LVEDD and LVEF between the low and high baseline hsCRP groups. Similar to the association of clinical outcome with hsCRP change, patients with low 6-month hsCRP values displayed the largest concurrent mean reductions in LVEDD and increases in LVEF (−6.4 ± 7.7 mm reduction in LVEDD and 11.0% ± 8.6 % increase in LVEF among those with low baseline hsCRP, and −7.1 ± 8.9 mm reduction in LVEDD and 11.1% ± 8.5 % increase in LVEF among those with high baseline hsCRP). In contrast, patients with high 6-month hsCRP values showed significantly lower reductions in LVEDD and increases in LVEF (−3.9 ± 5.9 mm reduction in LVEDD and 6.2% ± 8.3% increase in LVEF among those with low baseline hsCRP and −1.5 ± 9.8 mm reduction in LVEDD and 5.8% ± 9.4% increase in LVEF among those with high baseline hsCRP; *P* \< 0.01 for the overall difference). No significant differences in LVEDD reduction or LVEF increases were noted between the two groups with low (low/low and high/low) and high (low/high and high/high) 6-month hsCRP values.

###### Risk of death or heart failure hospitalizations in CRT patients by the change pattern of hsCRP.

  hsCRP change group                              HR     95%CI     *P*-value
  --------------------------------------------- ------ ---------- -----------
  High BL hsCRP and high 6-mo hsCRP, *n* = 56    7.6    3.1−18.5   \< 0.001
  Low BL hsCRP and high 6-mo hsCRP, *n* = 18     2.9    0.9−9.3      0.079
  High BL hsCRP and low 6-mo hsCRP, *n* = 31     1.4    0.4−5.0      0.576
  Low BL hsCRP and low 6-mo hsCRP, *n* = 93      1.00             

The multivariable cox regression analysis controls for age, gender, ischaemic cardiomyopathy, LBBB, NYHA class, LVEDD, LVEF, BUN, serum creatinine, NT-proBNP, β-blocker, and ACEI/ARB. ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; BL: baseline; CRT: cardiac resynchronization therapy; hsCRP: high sensitivity C-reactive protein; LBBB: left bundle branch block; LVEDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; NT-proBNP: N-terminal pro-brain natriuretic peptide; NYHA class: New York Heart Association functional class; 6-mo: 6-month.

![Comparison of absolute 6-month changes (mean) in LVEDD and LVEF according to the pattern of hsCRP change after 6 months of CRT.\
Absolute changes in LVEF and LVEDD were calculated as the difference between 6-month and baseline values. For comparison across the four groups, there were significant differences in LVEDD and LVEF changes (*P* = 0.003 and *P* = 0.002, respectively). BL: baseline; hsCRP: high sensitivity C-reactive protein; LVEDD: left ventricular end diastolic dimension; LVEF: left ventricular ejection fraction; 6: 6 months; (+): high hsCRP group (\> 3 mg/L); (−): low hsCRP group (≤ 3 mg/L).](jgc-11-04-296-g004){#jgc-11-04-296-g004}

4. Discussion {#s4}
=============

The current analysis explored several significant implications on the prognostic value of hsCRP levels for severe HF patients receiving CRT. The main findings can be summarized as follows. First, elevated hsCRP prior to CRT device implantation was identified as an independent determinant of adverse survival and more HF hospitalizations. Secondly, during 6-month follow-up, plasma levels of hsCRP were reduced or remained low in patients who were responders to CRT, yet a similar improvement was not observed among patients who were non-responders. Finally, the pattern of hsCRP changes after six months of CRT was significantly associated with the LV reverse parameters and subsequent clinical outcome.

To date, there have been relatively limited available studies regarding the relationship between baseline hsCRP levels and long-term outcome after CRT. Kamioka, *et al.*[@b13] found, in a small cohort of 65 patients, that hsCRP levels before CRT implantation were identified as the strongest predictive factor for cardiac death irrespective of other prognostic factors and that being in the high hsCRP group (\> 3 mg/L) at baseline was also associated with worse survival. This finding is similar to our results that hsCRP levels pre-CRT implant independently predict all-cause mortality or hospitalizations for HF following CRT after adjusting other established risk factors. What the exact potential mechanisms are for the observed the heightened risk of mortality and morbidity in patients with high hsCRP levels before CRT implantation currently remain unresolved. Several prior reports have demonstrated that elevated levels of hsCRP, as a biomarker of inflammation, was a powerful independent predictor of prognosis in chronic HF,[@b4]--[@b6] and a recent study has shown that increased hsCRP can directly predict progressive regional myocardial functional deterioration independent of confounding cardiovascular events.[@b14] The similar effect of hsCRP levels on the long-term outcome may also occur in CRT recipients, this hypothesis, however, cannot be directly confirmed by the current or prior results.

Moreover, a few previous studies have evaluated the association of changes in hsCRP levels after CRT and the subsequent clinical and echocardiographic response. In 140 patients undergoing CRT, Michelucci, *et al*.[@b15] reported that CRT reduced hsCRP status only in patients who showed LV reverse and reduction of hsCRP levels were associated with the absence of adverse cardiac events. On the contrary, Glick, *et al*.[@b16] reported that, although hsCRP decreased significantly within two weeks after CRT implantation, levels of hsCRP or their drop after two weeks of CRT did not correlate with clinical outcome. This discrepancy may possibly be due to the small sample size (32 patients) as well as a relatively short follow-up period. Another small observational study of 27 patients with advanced HF showed similar results to ours, in that hsCRP levels at 6-month follow up decreased in responders while such improvements were not observed in non-responders.[@b17] However, the authors did not investigate whether changes in hsCRP levels were associated with clinical outcome after CRT. The findings of these small retrospective studies were mostly congruent with our results that patients who showed significant LV reverse remodeling experienced significant reductions or maintained low 6-month hsCRP values, whereas patients who do not exhibit obvious cardiac reverse remodeling experienced a slight increase or remained high with regard to their 6-month hsCRP levels after CRT. Additionally, when patients were further stratified into four subgroups according to hsCRP change, we found that the pattern of hsCRP change from baseline to 6-month was associated with a lack of favorable LV reverse remodeling parameters with respect to LV dimensions and LVEF, and independently predicted subsequent all-cause mortality or HF hospitalizations. The pathophysiological mechanisms responsible for improvement of LV systolic function resulting in reduction or maintenance in hsCRP levels is likely complicated. Restoration of synchronization induced by CRT may lead to attenuated sympathetic and neurohormonal over-activation, reduced LV wall stress as well endothelial oxidative stress, which consequently exerts beneficial effects on the observed reduction in concentration of proinflammatory cytokines such as hsCRP.[@b18]--[@b20] In turn, the alleviation of inflammatory status may also result in improved clinical prognosis after CRT. Further studies are needed to elucidate the mechanisms underlying the changes in hsCRP levels and LV reverse remodeling as well as prognosis in patients undergoing CRT.

4.1. Study limitations {#s4a}
----------------------

Firstly, this study is a nonrandomized retrospective analysis, and it involved a relatively small sample size, which may lead to statistical limitations and subsequently affect our findings. Moreover, the present study was only designed to examine the hsCRP levels but not to other inflammatory biomarkers such as IL-6, TNF-α and TGF-1β which have also been identified as stronger predictors of clinical events in patients with advanced HF treated with CRT.[@b15],[@b21],[@b22] Furthermore, although debate exists regarding the clinical utility of different hsCRP cut-off values for predicting a worse outcome, we used a conventional cut point of 3.0 mg/L for the definition of high versus low hsCRP in current study. Additionally, the measurement of 6-month follow-up hsCRP values and echocardiographic parameters was not available for the whole patients which may potentially influence our conclusions. Finally, further studies are needed to elucidate the underlying pathophysiologic mechanisms of the interaction between hsCRP levels and LV reverse remodeling as well as clinical prognosis in patients undergoing CRT.

4.2. Conclusions {#s4b}
----------------

We have shown that hsCRP levels at baseline could predict the risk of death or HF hospitalizations in CRT recipients. In addition, a reduction measured at 6-months or maintenance of low hsCRP levels was observed in responders to CRT, and patients who had persistently high or exhibited an increase in hsCRP levels showed inferior LV reverse remodeling and subsequently had an increase in adverse clinical outcomes. Taken together, our results suggest that the important prognostic information can be obtained via an early assessment of hsCRP levels before and after CRT implantation and that this information may be useful for risk stratification and could influence clinical management strategies in CRT recipients.
